OptimizeRx Co. (NASDAQ:OPRX) Receives Consensus Rating of “Moderate Buy” from Analysts

OptimizeRx Co. (NASDAQ:OPRX) has been given an average recommendation of “Moderate Buy” by the nine brokerages that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $9.06.

Several research firms recently weighed in on OPRX. Lake Street Capital restated a “buy” rating and issued a $11.00 target price on shares of OptimizeRx in a report on Tuesday, December 24th. B. Riley dropped their price target on OptimizeRx from $17.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, December 24th. Stifel Nicolaus dropped their price target on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 price target on shares of OptimizeRx in a research report on Thursday, February 6th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $6.00 price target (down from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th.

OptimizeRx Stock Down 6.6 %

OPRX opened at $5.78 on Friday. The business has a 50 day moving average price of $5.43 and a 200 day moving average price of $6.25. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $16.65. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The firm has a market cap of $106.47 million, a P/E ratio of -4.35 and a beta of 1.38.

Insider Activity

In other news, CEO William J. Febbo acquired 20,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the completion of the transaction, the chief executive officer now owns 601,253 shares in the company, valued at approximately $3,012,277.53. This trade represents a 3.44 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 6.10% of the stock is currently owned by company insiders.

Institutional Trading of OptimizeRx

A number of institutional investors and hedge funds have recently modified their holdings of OPRX. Whetstone Capital Advisors LLC acquired a new stake in OptimizeRx in the 4th quarter valued at $6,563,000. Royce & Associates LP acquired a new stake in OptimizeRx in the 4th quarter valued at $5,198,000. Rice Hall James & Associates LLC boosted its stake in OptimizeRx by 24.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock valued at $4,751,000 after buying an additional 119,306 shares in the last quarter. Kennedy Capital Management LLC boosted its stake in OptimizeRx by 57.8% in the 4th quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company’s stock valued at $2,887,000 after buying an additional 217,676 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in OptimizeRx by 9.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 444,167 shares of the company’s stock valued at $2,159,000 after buying an additional 39,740 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.